Citigroup’s Intercure INCR Stock Holding History

Citigroup’s Portfolio INCR Stock Details INCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-521	Closed	-$987	–	5888
2024 Q3	$987	Buy	+521	New	+$1.09K	﹤0.01%	5451
2022 Q4	–	Sell	-36	Closed	–	–	5851
2022 Q3	$0	Buy	+36	New	+$196	﹤0.01%	6065
2022 Q2	–	Sell	-5,124	Closed	-$36K	–	6423
2022 Q1	$36K	Buy	5,124 +5,071	+9,568%	+$33.5K	﹤0.01%	4876
2021 Q4	$0	Buy	+53	New	+$380	﹤0.01%	5969

Other funds holding INCR

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Citigroup's INCR Position: Q4 2024 in Review

Citigroup sold out of Intercure (INCR) in Q4 2024, closing a stake of 521 shares — an estimated $987 sold.

Citigroup first reported a position in INCR in Q4 2021 and held it in 4 quarters. The position peaked at $36K in Q1 2022. 17 funds tracked by Wall St. Rank hold INCR as of Q4 2024.

Citigroup reported no remaining Intercure position as of Q4 2024 after selling out during the quarter.
Citigroup sold 521 Intercure shares in Q4 2024, an estimated $987.
Citigroup first reported a position in Intercure in Q4 2021 and held it in 4 quarters.
Citigroup's Intercure position peaked at $36K in Q1 2022.
17 funds tracked by Wall St. Rank held Intercure as of Q4 2024.

Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.